Literature DB >> 19058209

Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease.

Melissa J Frei-Jones1, Joshua J Field, Michael R DeBaun.   

Abstract

BACKGROUND: The National Association of Children's Hospitals and Related Institutions (NACHRI) established hospital readmission within 30 days as a benchmark for quality care in children with Sickle Cell Disease (SCD). Among children with SCD, limited data exists to identify risk factors for readmission and whether they are modifiable. PROCEDURE: We performed a retrospective cohort study to identify risk factors for readmission. All admissions for children with SCD in a 1-year period were reviewed; cases were defined as children with SCD readmitted within 30 days after their first admission during the study period and controls, children with SCD who were not readmitted.
RESULTS: We identified 30 cases and 70 controls. No difference in demographic data was found between groups. The most common admission and readmission diagnosis was pain, 78 and 70%, respectively. The greatest risk factor for readmission was no outpatient hematology follow-up within 30 days of discharge (OR 7.7, 95% CI 2.4-24.4). A diagnosis of asthma was also a risk factor for readmission (OR 2.9, 95% CI 1.2-7.3). Patients who required supplemental oxygen to maintain saturations in the normal range and were on room air for < or =24 hr at discharge were also more likely to be readmitted (OR 3.3, 95% CI 1.1-9.7). Multivariate analysis identified lack of outpatient follow-up and disease severity, defined as > or =3 admissions in the previous 12 months as predictors for readmission (R(2) = 0.41).
CONCLUSIONS: Potentially modifiable risk factors exist to decrease the rate of readmission of children with SCD admitted to the hospital for pain. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19058209      PMCID: PMC2730199          DOI: 10.1002/pbc.21854

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  12 in total

1.  Predictors of treatment adherence among asthma patients in the emergency department.

Authors:  K B Schmaling; N Afari; A W Blume
Journal:  J Asthma       Date:  1998       Impact factor: 2.515

2.  Health-related quality of life in children with sickle cell disease: child and parent perception.

Authors:  Julie A Panepinto; Kerry M O'Mahar; Michael R DeBaun; Fausto R Loberiza; J P Scott
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

3.  Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance.

Authors:  Samir K Ballas; Margaret Lusardi
Journal:  Am J Hematol       Date:  2005-05       Impact factor: 10.047

4.  Pain in sickle cell disease. Rates and risk factors.

Authors:  O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

5.  Factors associated with sickle cell disease mortality among hospitalized Angolan children and adolescents.

Authors:  J C Carlos Van-Dunem; J G B Alves; Luis Bernardino; José Natal Figueiroa; Cynthia Braga; Maria de Lourdes Pires do Nascimento; Sérgio José da Silva
Journal:  West Afr J Med       Date:  2007 Oct-Dec

6.  Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Authors:  Thomas V Adamkiewicz; Sharada Sarnaik; George R Buchanan; Rathi V Iyer; Scott T Miller; Charles H Pegelow; Zora R Rogers; Elliott Vichinsky; John Elliott; Richard R Facklam; Katherine L O'Brien; Benjamin Schwartz; Chris A Van Beneden; Michael J Cannon; James R Eckman; Harry Keyserling; Kevin Sullivan; Wing-Yen Wong; Winfred C Wang
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

7.  Does a clinical pathway improve the quality of care for sickle cell anemia?

Authors:  John Patrick T Co; Kevin B Johnson; Anne K Duggan; James F Casella; Modena Wilson
Journal:  Jt Comm J Qual Saf       Date:  2003-04

8.  Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.

Authors:  J C Bernini; Z R Rogers; E S Sandler; J S Reisch; C T Quinn; G R Buchanan
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

9.  Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients.

Authors:  Y M Yang; A K Shah; M Watson; V N Mankad
Journal:  Public Health Rep       Date:  1995 Jan-Feb       Impact factor: 2.792

10.  Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.

Authors:  John J Strouse; Clifford M Takemoto; Jeffrey R Keefer; Gregory J Kato; James F Casella
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

View more
  35 in total

Review 1.  A framework of pediatric hospital discharge care informed by legislation, research, and practice.

Authors:  Jay G Berry; Kevin Blaine; Jayne Rogers; Sarah McBride; Edward Schor; Jackie Birmingham; Mark A Schuster; Chris Feudtner
Journal:  JAMA Pediatr       Date:  2014-10       Impact factor: 16.193

2.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

3.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

4.  Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation.

Authors:  Amy Sobota; Dionne A Graham; Ellis J Neufeld; Matthew M Heeney
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

Review 5.  Rigorous and practical quality indicators in sickle cell disease care.

Authors:  Suzette O Oyeku; Elissa Z Faro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.

Authors:  Samir K Ballas; Robert L Bauserman; William F McCarthy; Oswaldo L Castro; Wally R Smith; Myron A Waclawiw
Journal:  J Pain Symptom Manage       Date:  2010-12       Impact factor: 3.612

7.  Adult emergency department patients with sickle cell pain crisis: results from a quality improvement learning collaborative model to improve analgesic management.

Authors:  Paula Tanabe; John W Hafner; Zoran Martinovich; Nicole Artz
Journal:  Acad Emerg Med       Date:  2012-04       Impact factor: 3.451

8.  Pediatric readmission prevalence and variability across hospitals.

Authors:  Jay G Berry; Sara L Toomey; Alan M Zaslavsky; Ashish K Jha; Mari M Nakamura; David J Klein; Jeremy Y Feng; Shanna Shulman; Vincent W Chiang; Vincent K Chiang; William Kaplan; Matt Hall; Mark A Schuster
Journal:  JAMA       Date:  2013-01-23       Impact factor: 56.272

9.  Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.

Authors:  Jifang Zhou; Jin Han; Edith A Nutescu; Victor R Gordeuk; Santosh L Saraf; Gregory S Calip
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

10.  Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate.

Authors:  Melissa J Frei-Jones; Joshua J Field; Michael R DeBaun
Journal:  Pediatr Blood Cancer       Date:  2009-09       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.